GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Current Stem Cell Research & Therapy, Bentham Science Publishers Ltd., Vol. 18, No. 6 ( 2023-08), p. 787-799
    Abstract: Breast cancer stem cells (BCSCs) are heterogeneous tumor-initiating cell subgroups of breast cancers that possess some stem cell markers and are sustained after chemotherapy. Due to BCSCs being sufficient for tumor relapse, and given that the biological behaviors of BCSCs are so complex, it is critical to figure out exactly how they work, learn more about their cell biology, and discover biomarkers and strategies for explicitly targeting and destructing cancer stem cells. In order to accomplish innovative treatment for breast cancer, it is also essential to target BCSCs. Despite the vast quantities of BCSC target chemicals, their therapeutic implementation is limited due to off-target behavior and bioavailability issues. Targeted drug delivery systems based on nanoparticles have advantages for transporting anti-BCSC materials, especially to targeted locations. Hence, breast cancer therapy using a nanoparticle-based BCSCs targeting system is a promising strategy. Such targeted drug delivery systems can resolve the biodistribution obstacles of nanosystems. Throughout this paper, we highlight various strategies for targeting BCSCs utilizing nano-based systems. In conclusion, issues about the inadequate stability of nanoparticles and the possibility of loaded drug leakage during delivery systems have yet to be answered. More fundamental and applied research, and proper methods such as coating or surface modification are required.
    Type of Medium: Online Resource
    ISSN: 1574-888X
    Language: English
    Publisher: Bentham Science Publishers Ltd.
    Publication Date: 2023
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    Bentham Science Publishers Ltd. ; 2023
    In:  Current Diabetes Reviews Vol. 19, No. 3 ( 2023-03)
    In: Current Diabetes Reviews, Bentham Science Publishers Ltd., Vol. 19, No. 3 ( 2023-03)
    Abstract: This systematic review aimed to appraise and recapitulate all research investigations to elucidate the effects of Sesamum indicum preparations on managing the cardiometabolic syndrome of Diabetes mellitus (DM) and metabolic syndrome (MetS). Methods: A systematic review was carried out in a Cochrane fashion and in compliance with the PRISMA checklist using the published academic works in PubMed/MEDLINE, WOS, SCOPUS, and EMBASE databases that were searched up to June 2021. Abstracts that met PICO criteria for qualitative studies were duplicate reviewed for data extraction to assess the quality and details of the study. Results: Sesamum indicum preparations and its bioactive lignans, such as sesamin, sesamol, and pinoresinol, were found to possess anti-hyperglycemic, anti-hyperlipidemia, anti-inflammatory, antioxidative, anti-hypertensive, cardioprotective, and hepatoprotective effects both in patients with T2DM as well as in experimental animal models with T1DM and MetS. The incorporation of sesame oil as a natural adjuvant can be effective in improving vascular reactivity and aortic permeability, reproductive parameters, and diabetic nephropathy, as well as modification of anthropometry indices. Therefore, sesame oil and bioactive lignans as combination therapy with drugs can exhibit synergistic effects and provide a favorable preference in clinical settings. Conclusion: Sesame oil and lignans present in it act in a dose-dependent manner. The best dosage to improve risk biomarkers of patients with T2DM and MetS is 30-35 ml daily of sesame oil or inclusion of sesame oil in daily dietary patterns up to 30% of total energy for 8-12 weeks and/or 200 mg daily of sesamin supplementation for eight weeks.
    Type of Medium: Online Resource
    ISSN: 1573-3998
    Language: English
    Publisher: Bentham Science Publishers Ltd.
    Publication Date: 2023
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    Bentham Science Publishers Ltd. ; 2022
    In:  Current Medicinal Chemistry Vol. 29, No. 8 ( 2022-03), p. 1436-1458
    In: Current Medicinal Chemistry, Bentham Science Publishers Ltd., Vol. 29, No. 8 ( 2022-03), p. 1436-1458
    Abstract: Triple-negative breast cancer (TNBC) is a highly resistant, lethal, and metastatic sub-division of breast carcinoma, characterized by the deficiency of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). In women, TNBC shows a higher aggressive behavior with poor patient prognosis and a higher recurrence rate during reproductive age. TNBC is defined by the presence of epithelial- to-mesenchymal-transition (EMT), which shows a significant role in cancer progression. At the epigenetic level, TNBC is characterized by epigenetic signatures, such as DNA methylation, histone remodeling, and a host of miRNA, MiR-193, LncRNA, HIF- 2α, eEF2K, LIN9/NEK2, IMP3, LISCH7/TGF-β1, GD3s, KLK12, mediated regulation. These modifications either are silenced or activate the necessary genes that are prevalent in TNBC. The review is based on epigenetic mediated mechanistic changes in TNBC. Furthermore, Thymoquinone (TQ), Regorafenib, Fangjihuangqi decoction, Saikosaponin A, and Huaier, etc., are potent antitumor natural compounds extensively reported in the literature. Further, the review emphasizes the role of these natural compounds in TNBC and their possible epigenetic targets, which can be utilized as a potential therapeutic strategy in the treatment of TNBC.
    Type of Medium: Online Resource
    ISSN: 0929-8673
    Language: English
    Publisher: Bentham Science Publishers Ltd.
    Publication Date: 2022
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: The Open Public Health Journal, Bentham Science Publishers Ltd., Vol. 17, No. 1 ( 2024-03-01)
    Abstract: This study aimed to shed light on how serum levels of interleukin-6 (IL-6), lactate dehydrogenase (LDH), and C-reactive protein (CRP) correlate with hemoglobin oxygen saturation percentage (SpO2) and the type of respiratory support received among COVID-19 patients hospitalized in COVID-19 intensive care units. Background The clinical care of patients who suffer from COVID-19 requires knowledge of laboratory findings and the way these findings are linked with the type of respiratory support. Methods This descriptive-analytical study was conducted using data from the clinical records of 31 patients hospitalized in the intensive care unit at 22 nd -Bahman Hospital in Khaf, Eastern Iran, during the first half of 2021. The study utilized a checklist developed by the researcher for data collection. The data were analyzed with Kolmogorov-Smirnov, independent t, one-way analysis of variance, and Tukey's post hoc statistical tests in the SPSS-22 statistical package. The significance level was established at p 〈 0.05. Results The mean CRP, LDH, and serum levels of IL-6 were significantly higher in COVID-19 patients with SpO2 〈 93 than in patients with SpO2 ≥93 (p 〈 0.05). Patients receiving intubation and non-invasive respiratory support exhibited significantly greater serum levels of IL-6, CRP, and LDH than patients receiving other respiratory support (p 〈 0.05). The mean CRP, serum levels of IL-6, and LDH were significantly lower among survivors than those who died (p 〈 0.01). Conclusion Understanding the relationship between the serum levels of IL-6, CRP, LDH, and SPO2 and the type of respiratory support can help predict the management of acute respiratory patients, but this decision-making method based on serum levels should be further investigated. and to be compared with the current methods of management of treatment of acute respiratory patients.
    Type of Medium: Online Resource
    ISSN: 1874-9445
    Language: English
    Publisher: Bentham Science Publishers Ltd.
    Publication Date: 2024
    detail.hit.zdb_id: 2575068-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Current Pharmaceutical Design, Bentham Science Publishers Ltd., Vol. 28, No. 45 ( 2022-12), p. 3618-3636
    Abstract: Insomnia is well-known as trouble in sleeping and enormously influences human life due to the shortage of sleep. Reactive Oxygen Species (ROS) accrue in neurons during the waking state, and sleep has a defensive role against oxidative damage and dissipates ROS in the brain. In contrast, insomnia is the source of inequity between ROS generation and removal by an endogenous antioxidant defense system. The relationship between insomnia, depression, and anxiety disorders damages the cardiovascular systems' immune mechanisms and functions. Traditionally, polysomnography is used in the diagnosis of insomnia. This technique is complex, with a long time overhead. In this work, we have proposed a novel machine learning-based automatic detection system using the R-R intervals extracted from a single-lead electrocardiograph (ECG). Additionally, we aimed to explore the role of oxidative stress and inflammation in sleeping disorders and cardiovascular diseases, antioxidants’ effects, and the psychopharmacological effect of herbal medicine. This work has been carried out in steps, which include collecting the ECG signal for normal and insomnia subjects, analyzing the signal, and finally, automatic classification. We used two approaches, including subjects (normal and insomnia), two sleep stages, i.e., wake and rapid eye movement, and three Machine Learning (ML)-based classifiers to complete the classification. A total number of 3000 ECG segments were collected from 18 subjects. Furthermore, using the theranostics approach, the role of mitochondrial dysfunction causing oxidative stress and inflammatory response in insomnia and cardiovascular diseases was explored. The data from various databases on the mechanism of action of different herbal medicines in insomnia and cardiovascular diseases with antioxidant and antidepressant activities were also retrieved. Random Forest (RF) classifier has shown the highest accuracy (subjects: 87.10% and sleep stage: 88.30%) compared to the Decision Tree (DT) and Support Vector Machine (SVM). The results revealed that the suggested method could perform well in classifying the subjects and sleep stages. Additionally, a random forest machine learning-based classifier could be helpful in the clinical discovery of sleep complications, including insomnia. The evidence retrieved from the databases showed that herbal medicine contains numerous phytochemical bioactives and has multimodal cellular mechanisms of action, viz., antioxidant, anti-inflammatory, vasorelaxant, detoxifier, antidepressant, anxiolytic, and cell-rejuvenator properties. Other herbal medicines have a GABA-A receptor agonist effect. Hence, we recommend that the theranostics approach has potential and can be adopted for future research to improve the quality of life of humans.
    Type of Medium: Online Resource
    ISSN: 1381-6128
    Language: English
    Publisher: Bentham Science Publishers Ltd.
    Publication Date: 2022
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    Online Resource
    Online Resource
    Bentham Science Publishers Ltd. ; 2021
    In:  Current Medicinal Chemistry Vol. 28, No. 12 ( 2021-04), p. 2392-2408
    In: Current Medicinal Chemistry, Bentham Science Publishers Ltd., Vol. 28, No. 12 ( 2021-04), p. 2392-2408
    Abstract: The last couple of months have witnessed the world in a state of virtual standstill. The SARS-CoV-2 virus has overtaken the globe to economic and social lockdown. Many patients with COVID-19 have compromised immunity, especially in an aged population suffering from Parkinson's disease (PD). : Alteration in dopaminergic neurons and deficiency of dopamine in PD patients are the most common symptoms affecting 1% population above the age of 60 years. The compromised immune system and inflammatory manifestation in PD patients make them an easy target. The most common drugs under trial for COVID-19 are remdesivir, favipiravir, chloroquine and hydroxychloroquine, azithromycin along with adjunct drugs like amantadine with some monoclonal antibodies. : Presently, clinically US FDA approved drugs in PD include Levodopa, catechol-O-methyl transferase (COMT) inhibitors, (Entacapone and Tolcapone), dopamine agonists (Bromocriptine, Ropinirole, Pramipexole, and Rotigotine), monoamine oxidase B (MAO-B) inhibitors (Selegiline and Rasagiline), amantadine and antimuscarinic drugs. The drugs have established mechanisms of action on PD patients with known pharmacodynamics and pharmacokinetic properties along with dose and adverse effects. : Conclusion and relevance of this review focus on the drugs that can be tried on PD patients with SAR CoV-2 infection, in particular, amantadine that has been approved by all the developed countries as a common drug possessing both antiviral properties by downregulation of CTSL, lysosomal pathway disturbance and change in pH necessary to uncoat the viral proteins and anti- Parkinson properties. To deal with the significant prognostic adverse effect of SARS-CoV-2 on PD, the present-day treatment options, clinical presentation and various mechanisms are the need of the hour.
    Type of Medium: Online Resource
    ISSN: 0929-8673
    Language: English
    Publisher: Bentham Science Publishers Ltd.
    Publication Date: 2021
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Current Drug Therapy, Bentham Science Publishers Ltd., Vol. 16, No. 3 ( 2021-10-26), p. 280-290
    Abstract: The objective of this study is to determine if previous exposure to sulfur mustard (SM) gas increases the pathogenesis of COVID-19 by comparing clinical characteristics, laboratory findings, and imaging data between SM-exposed survivors and other patients with COVID-19. Methods: This case-control study was conducted in Baqiyatallah hospital, Tehran, Iran, from 26th Feb – 26th March 2020. The case group composed of 60 SM-exposed survivors infected with COVID-19, and the control group was composed of 60 patients with COVID-19. Groups were matched for demographic (including age and gender) and comorbidity variables except for lung disease which was higher in the case group. The clinical characteristics, laboratory findings, and imaging manifestations, as well as outcomes, were compared between the two groups. Results: While the majority of patients in the case and control groups had at least one comorbidity like diabetes, hypertension, or heart disease, only lung disease was significantly higher in the case than in the control group (P=0.001). Patients in both groups displayed a variety of symptoms on arrival. Only chest pain was significantly more frequent in case patients than those in the control group. The levels of Neutrophils, ESR, BS, AST, LDH, and CRP in both groups were higher, and Na levels were lower than the normal range. Neutrophils were significantly higher in the case than in the control group (p=0.02). The BUN level was significantly lower in the control than in the case group (p=0.04). Other laboratory findings were within their normal ranges and similar in both groups. Significantly more patients in the case group showed early-stage opacities than those in the control group (p=.03). There were no significant differences in treatment or outcomes between the two groups. Conclusion: Most clinical characteristics, outcomes, and laboratory findings of COVID-19 in SMexposed survivors, were similar to those in the non-exposed. While these findings suggest that sulfur mustard gas exposure does not significantly affect the prognosis of the disease, the limitations and sample size of the current study may warrant additional investigations.
    Type of Medium: Online Resource
    ISSN: 1574-8855
    Language: English
    Publisher: Bentham Science Publishers Ltd.
    Publication Date: 2021
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Recent Patents on Anti-Cancer Drug Discovery, Bentham Science Publishers Ltd., Vol. 18 ( 2023-08-03)
    Abstract: Cancer is one of the leading causes of mortality and morbidity worldwide, affecting millions of people physically and financially every year. Over time, many anticancer treatments have been proposed and studied, including synthetic compound consumption, surgical procedures, or grueling chemotherapy. Although these treatments have improved the daily life quality of patients and increased their survival rate and life expectancy, they have also shown significant drawbacks, including staggering costs, multiple side effects, and difficulty in compliance and adherence to treatment. Therefore, natural compounds have been considered a possible key to overcoming these problems in recent years, and thorough research has been done to assess their effectiveness. In these studies, scientists have discovered a meaningful interaction between several natural materials and signal transducer and activator of transcription 3 molecules. STAT3 is a transcriptional protein that is vital for cell growth and survival. Mechanistic studies have established that activated STAT3 can increase cancer cell proliferation and invasion while reducing anticancer immunity. Thus, inhibiting STAT3 signaling by natural compounds has become one of the favorite research topics and an attractive target for developing novel cancer treatments. In the present article, we intend to comprehensively review the latest knowledge about the effects of various organic compounds on inhibiting the STAT3 signaling pathway to cure different cancer diseases.
    Type of Medium: Online Resource
    ISSN: 1574-8928
    Language: English
    Publisher: Bentham Science Publishers Ltd.
    Publication Date: 2023
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    Online Resource
    Online Resource
    Bentham Science Publishers Ltd. ; 2023
    In:  Anti-Cancer Agents in Medicinal Chemistry Vol. 23, No. 1 ( 2023-01), p. 15-36
    In: Anti-Cancer Agents in Medicinal Chemistry, Bentham Science Publishers Ltd., Vol. 23, No. 1 ( 2023-01), p. 15-36
    Abstract: Cyclooxygenase-2 (COX-2) is a key-type enzyme playing a crucial role in cancer development, making it a target of high interest for drug designers. In the last two decades, numerous selective COX-2 inhibitors have been approved for various clinical conditions. However, data from clinical trials propose that the prolonged use of COX-2 inhibitors is associated with life-threatening cardiovascular side effects. The data indicate that a slight structural modification can help develop COX-2 selective inhibitors with comparative efficacy and limited side effects. In this regard, secondary metabolites from natural sources offer great hope for developing novel COX-2 inhibitors with potential anticancer activity. In recent years, various nature-derived organic scaffolds are being explored as leads for developing new COX-2 inhibitors. The current review attempts to highlight the COX-2 inhibition activity of some naturally occurring secondary metabolites, concerning their capacity to inhibit COX-1 and COX-2 enzymes and inhibit cancer development, aiming to establish a structure-activity relationship.
    Type of Medium: Online Resource
    ISSN: 1871-5206
    Language: English
    Publisher: Bentham Science Publishers Ltd.
    Publication Date: 2023
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    Online Resource
    Online Resource
    Bentham Science Publishers Ltd. ; 2010
    In:  The Open Cardiovascular Medicine Journal Vol. 4, No. 1 ( 2010-2-23), p. 38-44
    In: The Open Cardiovascular Medicine Journal, Bentham Science Publishers Ltd., Vol. 4, No. 1 ( 2010-2-23), p. 38-44
    Abstract: Inflammatory biomarkers play a pivotal role in atherosclerotic lesions. The plasma levels of these markers are predictive of adverse outcomes such as myocardial infarction and cardiovascular death. The immune system is involved at all stages of atherogenesis via activation of monocytes/macrophages and T lymphocytes.Circulating proinflammatory cytokines and chemokines produced by these cells interact with specific receptors on various cells and activate specific signaling pathways, leading to inflammation-induced atherosclerotic lesions. Recent studies have focused on predictive value of inflammatory biomarkers such as C-reactive protein and interleukin-6. These biomarkers were shown to be associated with poor quality of life and predictive of adverse events in coronary atherosclerosis and left ventricular dysfunction. Vascular predictive value of other numerous inflammatory markers is being investigated. We herein analyze the role of several mediators of inflammation, affecting vascular functions and leading toward atherosclerotic lesions.
    Type of Medium: Online Resource
    ISSN: 1874-1924
    Language: English
    Publisher: Bentham Science Publishers Ltd.
    Publication Date: 2010
    detail.hit.zdb_id: 2430362-8
    detail.hit.zdb_id: 2396047-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...